FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285178354> ?p ?o ?g. }

• W4285178354 endingPage "389" @default.
• W4285178354 startingPage "389" @default.
• W4285178354 abstract "Dear Sir, In response to the correspondence by Udwadia Zarir and Jennifer[1] “India should speed up access to bedaquiline based all-oral regimens, not procrastinate further,” I would like to submit that my key message in the Editorial was grossly misinterpreted by authors. The article “WHO consolidated guidelines on tuberculosis 2020 moving towards fully oral regimens: Should country act in hurry”[2] have been written with concern to save bedaquiline for long-term use in the management of drug-resistant tuberculosis. The article does not question the efficacy of bedaquiline in the management of drug-resistant tuberculosis with its judicious use. The same concern has been expressed internationally too, on rolling out WHO consolidated guidelines, Kranzer et al.[3] have written “New World Health Organization Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared?” and Andres et al.[4] have commented, “Bedaquiline Resistant-Tuberculosis: Dark Clouds on the Horizon” both the articles published in prestigious American Journal of Respiratory and Critical Care Medicine. The same enthusiasm was there when rifampicin was discovered for treatment for tuberculosis. Drug-resistant tuberculosis (DR-TB) was not a major problem till year 1997–2000 when RNTCP was rolled out with weaker regimens, as a result of which India has become home to 24% of world’s Multi DR-TB (MDR-TB)[5] problem, second highest in the world within 20 years of its implementation (WHO Global TB Report 2019). The Editorial[2] answers almost all the questions raised by Udwadia and Furin, however for the sake of clarity I would like to respond further. Udwadia and Furin write about touting of Bangladesh regimen, there is no question of touting it, there are enough published data on the efficacy of this regimen in programmatic management of DR-TB in many countries, over 80 countries are implementing short MDR-regimen maintaining a cure rate of over 80%[678910] and the same has been proven in well-controlled clinical study STREAM (a trial of Shorter Regimen for Rifampicin-Resistant Tuberculosis).[11] This regimen has been suggested to buy time awaiting results of large number of clinical trials in pipeline including TB-PRACTECAL,[12] SIMPLICI-TB,[13] ZeNIX,[14] NEXT-TB,[15] STREAM II,[16] END-TB,[17] MDR-END,[18] and BEAT TB[19] the results of which will be available by end of 2022. By this time country can establish a strong infrastructure of DST laboratories for DST to bedaquiline, clofazimine, linezolid, and delamanid as WHO validated accurate reliable and reproducible methods have been established for these drugs (WHO consolidated guidelines on Drug-Resistant TB, 2020).[20] Currently, bedaquiline DST is available at only 3 national reference laboratories, rolling out of WHO Consolidated Guidelines 2020 in such situation without the establishment of DST methods for drugs used in the regimen (s) may result in the development of bedaquiline-resistant TB which will be a disaster for the nation. Primary bedaquiline-resistance exists in 5%–6% of drug-resistant TB cases[212223] and insufficient protection of bedaquiline-clofazimine (BDQ/CFZ) by the remaining companion drugs because of resistance or drug toxicity especially to floroquinolone and linezolid, amplification of resistance to BDQ/CFZ is likely to occur.[4] Many countries that have rolled out bedaquiline containing regimens largely in the absence of programmatic drug-susceptibility testing (DST) are facing problems of high frequency of acquired resistance to bedaquiline (15%–45%).[242526] Andres et al., in 2020[4] have proposed monthly phenotype and genotype testing to determine the emergence of resistance to drugs used and in an early view, Chesov et al.[27] in European Respiratory Journal (2021), have expressed that in high burden countries of tuberculosis bedaquiline resistance can emerge in more than 15% of mycobacterial TB complex strains obtained from follow-up isolates of MDR-TB patients and globally emerging resistant strains threaten the effectivity of novel MDR-TB treatment regimens. It is rightly written by Köser et al. that “THOSE WHO CANNOT REMEMBER THE PAST ARE CONDEMNED TO REPEAT IT.”[28] Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest." @default.
• W4285178354 created "2022-07-14" @default.
• W4285178354 creator A5071671623 @default.
• W4285178354 date "2022-01-01" @default.
• W4285178354 modified "2023-09-25" @default.
• W4285178354 title "Reply: Roll out of bedaquiline without drug susceptibility testing leads to emergence of bedaquiline-resistance in high burden countries with tuberculosis - Danger of losing a novel drug" @default.
• W4285178354 cites W2007102363 @default.
• W4285178354 cites W2052166920 @default.
• W4285178354 cites W2335742497 @default.
• W4285178354 cites W2563852803 @default.
• W4285178354 cites W2603525203 @default.
• W4285178354 cites W2770976846 @default.
• W4285178354 cites W2916062626 @default.
• W4285178354 cites W2921026546 @default.
• W4285178354 cites W2940491241 @default.
• W4285178354 cites W2953860631 @default.
• W4285178354 cites W2998166005 @default.
• W4285178354 cites W3005737253 @default.
• W4285178354 cites W3006427243 @default.
• W4285178354 cites W3082225610 @default.
• W4285178354 cites W3180155669 @default.
• W4285178354 cites W3196454029 @default.
• W4285178354 cites W3210800246 @default.
• W4285178354 doi "https://doi.org/10.4103/lungindia.lungindia_31_22" @default.
• W4285178354 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35848680" @default.
• W4285178354 hasPublicationYear "2022" @default.
• W4285178354 type Work @default.
• W4285178354 citedByCount "0" @default.
• W4285178354 crossrefType "journal-article" @default.
• W4285178354 hasAuthorship W4285178354A5071671623 @default.
• W4285178354 hasBestOaLocation W42851783541 @default.
• W4285178354 hasConcept C114851261 @default.
• W4285178354 hasConcept C142724271 @default.
• W4285178354 hasConcept C177713679 @default.
• W4285178354 hasConcept C2777975735 @default.
• W4285178354 hasConcept C2778607973 @default.
• W4285178354 hasConcept C2780544761 @default.
• W4285178354 hasConcept C2781069245 @default.
• W4285178354 hasConcept C3020294253 @default.
• W4285178354 hasConcept C512399662 @default.
• W4285178354 hasConcept C71924100 @default.
• W4285178354 hasConcept C86803240 @default.
• W4285178354 hasConcept C89423630 @default.
• W4285178354 hasConceptScore W4285178354C114851261 @default.
• W4285178354 hasConceptScore W4285178354C142724271 @default.
• W4285178354 hasConceptScore W4285178354C177713679 @default.
• W4285178354 hasConceptScore W4285178354C2777975735 @default.
• W4285178354 hasConceptScore W4285178354C2778607973 @default.
• W4285178354 hasConceptScore W4285178354C2780544761 @default.
• W4285178354 hasConceptScore W4285178354C2781069245 @default.
• W4285178354 hasConceptScore W4285178354C3020294253 @default.
• W4285178354 hasConceptScore W4285178354C512399662 @default.
• W4285178354 hasConceptScore W4285178354C71924100 @default.
• W4285178354 hasConceptScore W4285178354C86803240 @default.
• W4285178354 hasConceptScore W4285178354C89423630 @default.
• W4285178354 hasIssue "4" @default.
• W4285178354 hasLocation W42851783541 @default.
• W4285178354 hasLocation W42851783542 @default.
• W4285178354 hasLocation W42851783543 @default.
• W4285178354 hasLocation W42851783544 @default.
• W4285178354 hasLocation W42851783545 @default.
• W4285178354 hasOpenAccess W4285178354 @default.
• W4285178354 hasPrimaryLocation W42851783541 @default.
• W4285178354 hasRelatedWork W1896292939 @default.
• W4285178354 hasRelatedWork W2078287435 @default.
• W4285178354 hasRelatedWork W2132578776 @default.
• W4285178354 hasRelatedWork W2277252832 @default.
• W4285178354 hasRelatedWork W2903913877 @default.
• W4285178354 hasRelatedWork W2973028036 @default.
• W4285178354 hasRelatedWork W3049398979 @default.
• W4285178354 hasRelatedWork W3193036883 @default.
• W4285178354 hasRelatedWork W3208554283 @default.
• W4285178354 hasRelatedWork W4313441172 @default.
• W4285178354 hasVolume "39" @default.
• W4285178354 isParatext "false" @default.
• W4285178354 isRetracted "false" @default.
• W4285178354 workType "article" @default.